RT Journal Article
T1 Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
A1 Alten, Rieke
A1 Mariette, Xavier
A1 Lorenz, Hanns-Martin
A1 Nüßlein, Hubert
A1 Galeazzi, Mauro
A1 Navarro, Federico
A1 Chartier, Melanie
A1 Heitzmann, Julia
A1 Poncet, Coralie
A1 Rauch, Christiane
A1 Le Bars, Manuela
K1 Biologic
K1 Efficacy
K1 Predictor
K1 Remission
K1 Rheumatoid arthritis
AB Evaluate abatacept retention over 2 years in the AbataCepT In rOutiNe clinical practice (ACTION) study. ACTION was an international, observational study of patients with moderate-to-severe rheumatoid arthritis (RA) who initiated intravenous abatacept. Crude abatacept retention rates over 2 years were estimated using Kaplan-Meier analyses in biologic-naive and -failure patients. Clinically relevant risk factors and significant prognostic factors for retention were evaluated using a Cox proportional hazards multivariable model. Overall, 2350/2364 enrolled patients were evaluable; 673 (28.6%) were biologic naive and 1677 (71.4%) had prior biologic failure (1 biologic, 728/1677 [43.4%]; ≥ 2 biologics, 949/1677 [56.6%]). Abatacept retention rate (95% confidence interval [CI]) at 2 years was 47.9% (45.7, 50.0): 54.5% (50.4, 58.3) for biologic-naive vs 45.2% (42.7, 47.7) for biologic-failure patients (log-rank P  Abatacept initiation as earlier vs later line of therapy in RA may achieve higher 2-year retention rates. RF and anti-CCP seropositivity could predict increased abatacept retention, irrespective of treatment line. NCT02109666.
YR 2019
FD 2019-02-21
LK http://hdl.handle.net/10668/13603
UL http://hdl.handle.net/10668/13603
LA en
DS RISalud
RD Apr 5, 2025